Advancements in Perovskite-Based Cathode Materials for Solid Oxide Fuel Cells: A Comprehensive Review

The high-temperature solid oxide fuel cells (SOFCs) are the most efficient and green conversion technology for electricity generation from hydrogen-based fuel as compared to conventional thermal power plants. Many efforts have been made to reduce the high operating temperature (>800 °C) to intermediate/low operating temperature (400 °C Collapse

Key Words

• Ruddlesden-Popper phase
• Solid oxide fuel cell
• double perovskite
• electrochemical activity
• polarization resistance
• thermal expansion coefficient

Collapse

MESH Headings Collapse

Grants Collapse

Affiliation(s)

Ayesha Samreen Department of Physics, University of Peshawar, Peshawar, 25120, Pakistan
Muhammad Sudais Ali Department of Physics, University of Peshawar, Peshawar, 25120, Pakistan
Muhammad Huzaifa Department of Physics, University of Peshawar, Peshawar, 25120, Pakistan
Nasir Ali Research Center for Sensing Materials and Devices, Zhejiang Labs, Yuhang District, Nanhu, China
Bilal Hassan Department of Physics, University of Peshawar, Peshawar, 25120, Pakistan
Fazl Ullah Department of Physics, University of Peshawar, Peshawar, 25120, Pakistan
Shahid Ali Department of Physics, University of Peshawar, Peshawar, 25120, Pakistan
Nor Anisa Arifin Materials Engineering and Testing Group, TNB Research Sdn Bhd, No.1, Kawasan Institusi Penyelidikan, Jln Ayer Hitam, 43000, Kajang, Selangor, Malaysia

Collapse

Quantum-dot sensitized hierarchical NiO p–n heterojunction for effective photocatalytic performance

A facile and low-cost pseudo successive ionic layer adsorption and reaction technique was used to deposit cadmium sulfide quantum dots (CdS QDs) on hierarchical nanoflower NiO to form effective and intimate NiO/CdS, p–n heterojunctions.

Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting

Simple Summary

Food and Drug Administration (FDA) drug approvals from July 2007 to June 2019 were reviewed to identify oncology approvals, and trials with age details were reviewed for the study. We hypothesized that the clinical trials that do not report race are likely to suffer from a higher degree of age disparity. The study demonstrated that a significant number of clinical trials leading to cancer drug approvals suffer from racial and age disparity when compared to real-world populations and that the two factors may be interrelated. Age discrepancy between the clinical trial population and the real-world population was higher for studies that did not report race (mean difference −8.8 years (95% CI −12.6 to −5.0 years)) vs. studies that did report it. We recommend continued efforts to recruit diverse populations in clinical trials and make concerted efforts to implement national strategies in order to realize healthcare equity. In the meantime, detailed reporting of patient demographic characteristics in publications should be considered standard.

Abstract

Background: Concern exists that the clinical trial populations differ from respective cancer populations in terms of their age distribution affecting the generalizability of the results, especially in underrepresented minorities. We hypothesized that the clinical trials that do not report race are likely to suffer from a higher degree of age disparity. Methods: Food and Drug Administration (FDA) drug approvals from July 2007 to June 2019 were reviewed to identify oncology approvals, and trials with age details were selected. The outcomes studied were the weighted mean difference in age between the clinical trial population and real-world population for various cancers, the prevalence of race reporting and association of age and race reporting with each other. Results: Of the 261 trials, race was reported in 223 (85.4%) of the trials, while 38 trials (14.6%) had no mention of race. Race reporting improved minimally over time: 29 (85.3%) in 2007–2010 vs. 49 (80.3%) in 2011–2014 vs. 145 (85.4%) during the period 2015–2019 (p-value = 0.41). Age discrepancy between the clinical trial population and the real-world population was higher for studies that did not report race (mean difference −8.8 years (95% CI −12.6 to −5.0 years)) vs. studies that did report it (mean difference −5.1 years, (95% CI −6.4 to −3.7 years), p-value = 0.04). Conclusion: The study demonstrates that a significant number of clinical trials leading to cancer drug approvals suffer from racial and age disparity when compared to real-world populations, and that the two factors may be interrelated. We recommend continued efforts to recruit diverse populations.

Genomics combined with a protein informatics platform to assess a novel pathogenic variant c.1024 A>G (p.K342E) in OPA1 in a patient with autosomal dominant optic atrophy

BACKGROUND

Autosomal Dominant Optic Atrophy (ADOA) is caused by mutations in the Optic Atrophy 1 Gene which disrupts the OPA1 protein. This disruption affects the normal function of the protein; impairs fusion of the mitochondrial inner membrane; and prevents normal OPA1 protein degradation. These events cause damage in retinal ganglion cells that could affect the patients with symptoms ranging from none to legally blind.

MATERIALS AND METHODS

Our study identifies a missense variant mutation, c.1024 A > G (p.K342E), in OPA1 gene causing ADOA. Diagnosed clinically in three family members and the presence of this mutation was confirmed in two members by genetic testing. Pathogenic variants in OPA1 impact the secondary protein structure and function by causing non-conservative amino acid substitutions. We also modeled this mutation and compared it to the wild type using statistical mechanics.

RESULTS AND CONCLUSIONS

The proband's pathogenic variant, c.1024 A > G (p.K342E), is located in the GTPase domain of OPA1 and causes changes in the protein structure by affecting the oligomerization pattern thus resulting in ADOA. Identifying the pathogenic potential of the missense mutations in the OPA1 gene using neoteric protein modeling techniques would help in the early detection of ADOA in patients who have family history of blindness. This action would help in providing early follow up, possible treatment in the future, and genetic counseling. Abbreviations: ADOA: Autosomal Dominant Optic Atrophy; CYCS: Caspase Activator Cytochrome C; OPA1: Optic Atrophy Gene 1; RGC: Retinal Ganglion Cells; VUS: Variant of Uncertain Significance.

Fabrication of graphene oxide coated quartz filter paper for enhanced adsorption of particulate matter

Airborne particulate matter has become an emerging issue globally due to environmental degradation and the health risk it causes. Volatilization of weakly adsorbed particles onto quartz filter paper (QFP) limits its performance. The adsorption of particulate matter (PM₁₀) onto QFP coated with different concentrations of graphene oxide (GO) was investigated to enhance the adsorption potential. Hummer's method was adopted to synthesize GO. QFPs were coated with different concentrations of GO using a spin coating technique to optimize the result. The morphology and microstructure of GO-QFP were characterized by various experimental techniques, like XRD, FTIR, EDX, and SEM. GO showed considerable affinity to aerosol particles for GO-QFP weighing 5 mg/ml, whereas adsorption of the coated samples before and after was significantly reduced. The high affinity to aerosol particles was due to dominated π-π interactions and the grooved regions formed on the GO layer. It was considered that the high surface to volume ratio of GO-QFP improves the adsorptive property of the QF and consequently enhances the performance of the filter paper.

Abstract P1-01-01: Systemic imaging fails to detect metastasis in early stage breast cancer

Background: Current NCCN guidelines for early stage breast cancer (Stage I and II) do not recommend routine systemic imaging in the absence of symptoms or abnormal labs suggestive of distant metastasis. This study aims to determine the frequency and appropriateness of these imaging studies performed, its impact on staging and the factors that influence physicians in ordering these imaging studies.

Methods: Patients with stage I and II breast cancer at initial presentation were retrospectively identified between years 2011-2015 from the tumor registry. Charts were reviewed to determine patients who got systemic imaging (CT scan, non-breast MRI, bone scan or PET scan) within 6 months of diagnosis. Provider notes and laboratory data were analyzed to establish the appropriateness of ordered imaging studies and if the imaging altered the stage. For each patient in the study, age at diagnosis, the grade of the breast tumor, hormonal receptor status and HER-2 status was documented. Statistical analysis was done using appropriate tests.

Results: A total of 1067 patient charts were screened, of which 882 were identified for inclusion in the study (544 stage I, 338 stage II). Amongst the cohort, 18.57% (101) of patients with stage I and 50.89% (172) of patients with stage II cancer received imaging studies within the first 6 months of diagnosis. Only 12.68% (69) of stage I patients and 18.24% (62) of stage II patients were judged appropriate for imaging based on symptoms and lab results suggesting metastasis. In the imaged cohort of Stage I patients, only 4.35% (3) of the appropriately imaged group and 13.33% (4) of the inappropriately imaged group had a change in stage. Similarly, in the Stage II cohort, only 4.84% (3) of the appropriately imaged group and 8.18% (9) of the inappropriately imaged group saw a change in state. The difference in stage change in the appropriately and inappropriately imaged groups was not statistically significant. (p = 0.11 for Stage I, p=0.41 for Stage II). Only 5.9% of Stage I and 2.9% of Stage II imaged patients changed to stage IV. Grade 1 patients were less likely to receive systemic imaging than grade 2 and 3 patients ((p <0.001). Similarly, the difference in imaging rates ordered in patients with ER and/or PR negative status versus ER and PR positive status was significant (p=0.0004). Triple negative (p <0.001) status and age≤ 50 years were statistically significant predictors of patients receiving imaging (p = 0.014). HER-2 status alone was not a significant predictor of getting imaged (p= 0.527).

Conclusions: We performed the first ever study to investigate a correlation between the appropriateness of ordered imaging studies in early stage breast cancer and its ability to detect a change in stage. Distant metastasis identification among stage I & II patients was extremely rare among both appropriately and inappropriately imaged groups. Our findings suggest a wide prevalence of inappropriately ordered imaging studies in Stage I and II breast cancer as well as limited utility for even appropriately ordered ones. Further, other factors such as grade of the tumor, ER/PR/HER2 status and age were found to be statistically significant predictors of whether patients received imaging studies.

Citation Format: Gaba AG, Kraft R, Stjern BK, Monu M, Gunderson MA, Hanish C, Samreen A, Paladugu G. Systemic imaging fails to detect metastasis in early stage breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-01-01.

Hybrid AgNPs/MEH-PPV nanocomplexes with enhanced optical absorption and photoluminescence properties

Fluorescent semiconducting conjugated polymer nanoparticles (CPNs) are promising candidates for enhanced luminescent devices and bioimaging.